Differential NOD/SCID mouse engraftment of peripheral blood CD34 + cells and JAK2V617F clones from patients with myeloproliferative neoplasms by Leung, AYH et al.
Title
Differential NOD/SCID mouse engraftment of peripheral blood
CD34 + cells and JAK2V617F clones from patients with
myeloproliferative neoplasms
Author(s) Fung, TK; Cheung, AMS; Kwong, YL; Liang, R; Leung, AYH
Citation Leukemia Research, 2010, v. 34 n. 10, p. 1390-1394
Issued Date 2010
URL http://hdl.handle.net/10722/123827
Rights Creative Commons: Attribution 3.0 Hong Kong License
GL
D
J
T
D
a
A
R
R
A
A
K
J
M
N
P
1
d
e
i
g
M
(
p
o
m
[
m
p
s
m
i
e
s
t
b
J
p
0
dARTICLE IN PRESSModelR-3771; No.of Pages5
Leukemia Research xxx (2010) xxx–xxx
Contents lists available at ScienceDirect
Leukemia Research
journa l homepage: www.e lsev ier .com/ locate / leukres
ifferential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and
AK2V617F clones from patients with myeloproliferative neoplasms
sz-Kan Fung, Alice M.S. Cheung, Yok-Lam Kwong, Raymond Liang, Anskar Y.H. Leung ∗
epartment of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road, Hong Kong, Hong Kong, China
r t i c l e i n f o
rticle history:
eceived 8 November 2009
eceived in revised form 20 January 2010
a b s t r a c t
We evaluated the NOD/SCID engraftment of CD34+ cells from polycythemia vera (PV) and secondary
polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood
CD34+ cells were transplanted intra-femorally. In the injected BM, successful engraftment (>0.1%)ccepted 26 January 2010
vailable online xxx
eywords:
AK2
yeloproliferative disease
occurred in 8/26 mice transplanted with CD34+ cells from 5/13 PV patients (median: 4.26%, range:
0.3–5.56%), in contrast to 0/14 mice from 9 SP patients (P=0.017). The engrafting PV cells were of multi-
lineage. JAK2V617F/total JAK2 ratios decreased after transplantation (initial: 65.9% versus 6-week: 13.0%,
P=0.001). Essential thrombocythemia (ET) BM cells also exhibited a similar decrease in JAK2V617F clone.
The results suggested that events in addition to JAK2V617F are involved in the pathogenesis of PV andOD/SCID mice
olycythemia vera
ET.
. Introduction
Chronic myeloproliferative diseases (MPD) are heterogeneous
iseases characterized by clonal proliferation at the hematopoi-
tic stem cell (HSC) level [1]. A gain-of-function V617F mutation
n the JH2 auto-regulatory domain of the Janus Kinase 2 (JAK2)
ene (JAK2V617F) is the commonest molecular abnormality in
PD, occurring in more than 90% patients with polycythemia vera
PV) and 50% patients with essential thrombocythemia (ET) and
rimary myelofibrosis (PMF); underscoring the pathogenetic role
f deregulated Jak2 [2–4]. JAK2V617F transgenic mice [5,6] and
ice receiving JAK2V617F-transduced bone marrow (BM) cells
2,7–9] developed PV and other MPD-like diseases. The JAK2V617F
utation has also been found in the primitive hematopoietic cell
opulation [10] as well as the hematolymphoid progenitors from
ome cases of PV [11], supporting the proposition that JAK2V617F
utation is a stem cell event.
The xenogeneic transplantation of human hematopoietic cells
nto immunodeficient mice has become a standard model for the
numeration of normal and neoplastic stem cells [12]. Two recent
tudies employing this model have examined the HSC origin ofPlease cite this article in press as: Fung T-K, et al. Differential NOD/SCID
clones from patients with myeloproliferative neoplasms. Leuk Res (2010),
he JAK2V617F mutation in MPD [13,14]. In particular, peripheral
lood (PB) CD34+ cells from PV patients were shown to contain
AK2V617F HSC, which could engraft and differentiate into multi-
le hematopoietic lineages in NOD/SCID mice. The data suggested
∗ Corresponding author. Tel.: +852 28 55 3347; fax: +852 29 74 1165.
E-mail address: ayhleung@hku.hk (A.Y.H. Leung).
145-2126/$ – see front matter © 2010 Elsevier Ltd. All rights reserved.
oi:10.1016/j.leukres.2010.01.028© 2010 Elsevier Ltd. All rights reserved.
spontaneous mobilization of HSC, and a comparison with similarly
mobilized HSC from patients without JAK2V617F may provide evi-
dence if the gene mutation has conferred engraftment superiority
to HSC. Moreover, PV and PMF were different in their lineage dif-
ferentiation programs and the clone size of the JAK2V617F HSC.
Information about JAK2V617F ET is currently lacking.
In this study, we examined HSC activity and JAK2V617F clone in
PV by comparing NOD/SCID mouse engraftment by PB CD34+ cells
frompatientswith JAK2V617FPVandsecondarypolycythemia (SP).
The latter was a JAK2V617F-negative non-neoplastic condition in
which erythropoiesis is stimulated by increased serum erythropoi-
etin. The change in JAK2V617F clone in PV upon NOD/SCID mouse
engraftment was also enumerated. Finally, we also compared the
HSC activity between PV, ET and PMF by examining their engraft-
ment and changes in JAK2V617F clone in NOD/SCID mice.
2. Materials and methods
2.1. Patients
CD34+ cells were obtained from PB of patients with JAK2V617F-positive PV and
SP. PB mononuclear cells (MNC) were purified by density gradient centrifugation.
CD34+ cells were isolated immunomagnetically (Miltenyi, Bergisch, Gladbach, Ger-
many) and were either transplanted directly or stored in liquid nitrogen until use.
BM MNCs were also prospectively collected from PV, ET and PMF patients. The
investigation was approved by the Institution Review Board in accordance with
the Declaration of Helsinki.mouse engraftment of peripheral blood CD34+ cells and JAK2V617F
doi:10.1016/j.leukres.2010.01.028
2.2. NOD/SCID mouse transplantation and enumeration of engraftment
PB CD34+ cells from PV and SP patients were transplanted into sublethally irra-
diated (250 cGy) 6–8 weeks old NOD/SCID mice (Jackson Laboratory, Bar Harbor,
Maine, USA) by direct intra-femoral injection as described [15]. Engraftment was
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ssessed 6–8 weeks after transplantation. Briefly, BM was flushed out from the
njected (right femur) and uninjected (left femur and bilateral tibias) bones and
ere processed separately. Red cells were lysed (BD Pharm LyseTM Lysing buffer, BD
iosciences, San Jose, CA, USA) and marrow cells were co-stained with human spe-
ific fluorescein isothiocyanate (FITC)–conjugated antihuman CD45 antibody (clone
D1) andmouse specificphycoerythrin (PE)-conjugatedantimouseCD45.1 antibody
clone A20) (BD Biosciences, San Jose, CA, USA) for 30min in ice, followed by flow
ytometry analysis. Successful human cell engraftmentwas defined by the presence
f more than 0.1% human CD45+ mouse CD45.1− cells in the recipient mouse BM.
n some experiments, human BM MNC or CD34+ cells from PV, ET and PMF patients
ere transplanted via an intravenous or intra-femoral route and engraftment was
imilarly enumerated.
.3. Real-time quantitative polymerase chain reaction (Q-PCR)
To quantify the JAK2V617F clone in engrafting human cells, genomic DNA was
xtracted from the mouse BM cells. Q-PCR was set up with the TaqMan Univer-
al PCR Master Mix (Applied Biosystems, Foster City, CA, USA), the genomic DNA
0.5L), the primers (200nmol/L) and TaqMan probe (100nmol/L), using the ABI
rism7700SequenceDetector (AppliedBiosystems, FosterCity, CA,USA). Sequences
f primers and probes used in Q-PCR and the PCR conditions have been described
reviously [16]. Standard curves for the quantification of JAK2 and JAK2V617F
lones were constructed by plotting the CTs against the logarithm of the starting
mount (0.05–500 fg) of pGEM-T plasmids containing either the JAK2 or JAK2V617F
equence. Thequantity of JAK2 and JAK2V617F cloneswasdeterminedby correlating
he CT values from the standard curves. Percentage of JAK2V617F clone in each sam-
le was calculated as the amount of JAK2V617F/(amount of JAK2V617F+ amount of
AK2). The Q-PCR was human specific and non-transplanted mouse marrow invari-
bly gave negative results.
.4. Amplification refractory mutation system PCR (ARMS-PCR)
In the latter part of the study in which BM MNC and CD34+ cells from PV, ET and
MF patients were transplanted intravenously into NOD/SCID mice, the JAK2V617F
lone before and after transplantationwas enumerated usingARMS-PCR, performed
or 40 cycles as described [17]. Comparison of the JAK2V617F clone relative to
otal JAK2 (JAK2V617F+ JAK2) was performed semi-quantitatively by comparing the
utant andwild-typePCRbands in the samesampleby the ImageJ program(Version
.38x, National Institutes of Health, USA). The ARMS-PCR was also human specific
nd non-transplanted mouse marrow invariably gave negative results.
.5. Correlation between ARMS-PCR and Q-PCR
As the enumeration of JAK2V617F clone by ARMS-PCR was only semi-
uantitative, we validated it by concomitant Q-PCR, where DNA was available. In a
otal of 53 samples, the burden of the JAK2V617F clonewas quantified by bothmeth-
ds. There was a significant correlation between ARMS-PCR and Q-PCR (R=0.899;
<0.001) (Fig. 1), validating the use of ARMS-PCR in this study.
.6. Statistical analysis
Data were expressed as mean± standard error of the mean (S.E.M.). Compar-
sons between numerical and categorical data were evaluated by Mann–Whitney’s
-test and 2 test. A P-value of <0.05 was considered statistically significant.
. Results
.1. Patient samplesPlease cite this article in press as: Fung T-K, et al. Differential NOD/SCID
clones from patients with myeloproliferative neoplasms. Leuk Res (2010),
PB samples from 13 PV and 9 SP patients undergoing thera-
eutic venesection were prospectively collected (Table 1). The two
roups of patients were similar in age and hemoglobin concentra-
ion. However, patientswith SPwere predominantlymale smokers
hereas patients with PV have significantly higher total white cell
able 1
linicopathologic characteristics of patients with polycythemia vera and secondary polyc
Polycythemia vera JAK2V617F in 13/13 cases
Patient number 13
Male:female* 6:5
Age (range, median) (years) 34–82, 61.5
Hemoglobin (g/dL) 19.6±0.77
White cell count (×109 L−1) 17.8±2.29
Platelet (×109 L−1) 516.1±76.45
* Identity of two patients with polycythemia vera and one patient with secondary polyFig. 1. Correlation between ARMS-PCR and real-time quantitative PCR. Every point
in the graph represents the simultaneous enumeration of JAK2V617F clone by real-
time Q-PCR (y-axis) and ARMS-PCR (x-axis) of one sample.
and platelet counts. Serumerythropoietin assay has not been a reg-
ular investigation in our institute and the levels were not available.
In addition, BM samples from 12 patients with JAK2V617F-positive
MPD (W.H.O. classification: PV=4; ET=3; PMF=5) were also
prospectively collected (Supplementary Materials: Table 1).
3.2. Engraftment of PV CD34+ cells in NOD/SCID xenogeneic
transplantation
To examine if PV CD34+ cells exhibited an engraftment advan-
tage, PBCD34+ cells were transplanted in comparable numbers
into irradiated NOD/SCID mice from patients with PV (median cell
dose =0.3×106 mouse−1, range: 0.075×106 to 1.5×106 mouse−1)
and SP (median cell dose =0.3×106 mouse−1, range: 0.1×106 to
1.0×106 mouse−1) via direct intra-femoral injection. In BM har-
vested from the mouse femur injected with human cells (injected
BM), 8/26 mice transplanted with 5/13 PBCD34+ cells from PV
patients engrafted (median: 4.26%, range: 0.3–5.56%), in con-
trast to 0/14 mice from 9 SP patients (P=0.017) (Fig. 2A). The
engrafting PV cells were capable of differentiating into myeloid
cells (CD45+CD33+: 31.6±9.0%), B-lymphoid cells (CD3−CD19+:
75.5±11.9%), as well as maintaining the primitive CD34+ pheno-
type (9.8±1.9%). In BM harvested from the other mouse femur and
tibias that had not been injectedwith human cells (uninjected BM),
4/26 mice transplanted with 3/13 PBCD34+ cells from PV patients
engrafted (median: 1.43%, range: 0.11–1.81%), in contrast to 0/14
mice from 9 SP patients (P=0.058) (Fig. 2B, also Table 2).
3.3. Reduction of JAK2V617F clone upon NOD/SCID engraftment
We next investigated if the JAK2V617F mutation conferredmouse engraftment of peripheral blood CD34+ cells and JAK2V617F
doi:10.1016/j.leukres.2010.01.028
engraftment advantage to PV cells in NOD/SCID mice. We com-
pared the JAK2V617F clone size in PV CD34+ cells in the initial
graft and 6 weeks after direct intra-femoral transplantation into
NOD/SCID mice. When the uninjected BM were analyzed, there
was a consistent decrease in the JAK2V617F clone after transplan-
ythemia.
Secondary polycythemia JAK2V617F in 0/9 cases P-value
9
8:0 0.045
46–78, 67.0 0.955
18.8±0.15 0.505
8.1±1.02 0.001
208.0±17.43 <0.001
cythemia was not available.
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Fig. 2. Engraftment of polycythemia vera (PV) and secondary polycythemia (SP)
PBCD34+ cells in NOD/SCID mice. (A and B) Differential engraftment by PB CD34+
cells from PV and SP patients. Mouse BM was harvested from either (A) injected
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fir (B) uninjected BM. Human engraftment is higher in PV than SP patients. The
ars represent the mean engraftment. (C and D) Percentages of JAK2V617F by real-
ime Q-PCR in PV samples before and after transplantation in (C) uninjected and (D)
njected BM of NOD/SCID mice.
ation (initial: median=65.9%; 6-week: median=13.0%, P=0.001)
Fig. 2C). When the injected BM was analyzed, the results were
ighly variable. The median JAK2V617F/(JAK2V617F+ JAK2) ratios
rom 17/26 paired samples were 65.9% and 32.0% in the initial and
-week samples respectively (P=0.079) (Fig. 2D).
.4. Transplantation of BM MNC from PV, ET and PMF patients
To compare the engraftment kinetics of the JAK2V617F clone
n PV, ET and PMF HSC, we also transplanted BM samples from
hese patients into NOD/SCID mice via an intravenous or intra-
emoral route. Owing to the small number of cells collected, CD34+
election was not performed, and only MNC were transplanted in
ost cases. Successful engraftment was detected in 8/9 recipient
ice in all four PV patients (median: 6.50%; range: 1.70–56.0%;
lso see Supplementary Materials: Table 2). The engrafting PV
ells from BM were also capable of differentiating into myeloid
ells (CD45+CD33+: 51.5±17.4%), B-lymphoid cells (CD3−CD19+:
3.9±16.4%)aswell asmaintaining theprimitiveCD34+ phenotype
11.0±7.63%). Similar to transplantation with PBCD34+ cells, a sig-
ificant decrease in JAK2V617F clonewas also notedwhenBMMNC
rCD34+ cells from4PVpatientswere transplanted intra-femorally
r intravenously into NOD/SCID mice (Fig. 3A).
When BM MNC from three ET patients were transplanted, 2/3
ases showed successful engraftment in four mice. Among the
our mice engrafting with two patient samples (Supplementary
aterials: Table 2), one of them showedmulti-lineage engraftmentPlease cite this article in press as: Fung T-K, et al. Differential NOD/SCID
clones from patients with myeloproliferative neoplasms. Leuk Res (2010),
mouse 6.1: CD33+ cells: 77.7%; CD3−CD19+ cells: 18.5% and CD34+
ells: 13.3%). Theother twomice showedonlymyeloid engraftment
Mouse 5.2: CD33+ cells: 50.0%; Mouse 6.2: CD33+ cells: 69.3%).
ineage analysis was not performed in one mouse. None of the
ve PMF samples showed successful human engraftment in sevenFig. 3. JAK2V617F clone of PV, ET and PMF BM cells before and after xenogeneic
transplantation. (A–C) Percentage of JAK2V617F by ARMS-PCR in (A) PV, (B) ET and
(C) PMF BM samples before and after transplantation.
mice. Similar to the PV cases, the frequency of JAK2V617F/total JAK2
clones in ET markedly diminished in the engrafting cells (Fig. 3B).
For PMF, despiteunsuccessful engraftmentbyflowcytometry crite-
ria (≥0.1%), human JAK2V617F could be detectable in the recipient
mouse BM and the clone was sustainable in five mice (Fig. 3C).
4. Discussion
In this study, we demonstrated that BM and PB cells from PV
patients were able to engraft into NOD/SCID mice via both intra-
venous and intra-femoral routes and differentiate into multiple
hematopoietic lineages. Similar observations have been reported
recently, supported the proposition that the JAK2V617F mutation
in PV occurred at the HSC level. Both the percentage of PV samples
and the absolute level of successful engraftment were remarkably
similar to those reported by Ishii et al. [13] but lower than those
by James et al. [14], suggesting that either depletion of NK cells
or the use of CD34+ cells of BM origin in the latter study might
lead to a more robust xenogeneic engraftment. This limitation
notwithstanding, there are a number of interesting observations
which may provide us with further insights into the pathogenesis
of JAK2V617F-positive MPD.
First, we demonstrated that PBCD34+ cells from patients with
PV but not SP engrafted in NOD/SCID mice. Previous studies have
shown that HSC in PV and PMF patients undergo spontaneous
mobilization [18], and that PB CD34+ cells could engraft into
NOD/SCID mice [13]. On the other hand, although G-CSF mobilized
CD34+ cells from health donors consistently engraft in NOD/SCID
mice [19], whether unmobilized CD34+ cells from patients with
non-neoplastic disease can also engraft is unclear. We addressed
this issue by examining venesection samples from SP patients, the
closest non-neoplastic control of PV patients. We believed that it
presented a valid control to evaluate the impact of JAK2V617F in PV
on NOD/SCID mouse engraftment. On the other hand, G-CSF mobi-
lized or bone marrow CD34+ cells are expectedly different frommouse engraftment of peripheral blood CD34+ cells and JAK2V617F
doi:10.1016/j.leukres.2010.01.028
unmobilized CD34+ and may introduce confounding factors in the
comparison, irrespective of the presence of JAK2V617F mutation.
Surprisingly, none of the 14 mice receiving 0.1–1.0×106 CD34+
cells from 9 SP patients engrafted, compared with 8/26 mice who
ARTICLE IN PRESSGModelLR-3771; No.of Pages5
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Table 2
Engraftment data of PBCD34+ cells from patients with polycythemia vera.
Patient Mouse Cell dose* (×106) Uninjected BM Injected BM
Engraftment (%)† JAK2V617F (%)‡ Engraftment (%)† JAK2V617F (%)‡
Before After Before After
1 1.1 0.1 <0.1 79.1 UD <0.1 79.1 UD
1 1.2 0.1 <0.1 79.1 UD <0.1 79.1 UD
2 2.1 0.1 0.24 36.7 UD 0.32 36.7 UD
2 2.2 0.1 <0.1 36.7 UD <0.1 36.7 UD
2 2.3 0.3 <0.1 36.7 0 0.31 36.7 0.5
2 2.4 0.3 N/A 36.7 0 NA 36.7 0
2 2.5 0.3 <0.1 36.7 UD <0.1 36.7 40.2
3 3.1 0.5 <0.1 37.7 UD <0.1 37.7 UD
3 3.2 0.5 <0.1 37.7 UD <0.1 37.7 UD
4 4.1 0.22 0.11 82.2 UD 5.27 82.2 25.6
4 4.2 0.22 1.43 82.2 36.1 5.56 82.2 25.4
5 5.1 0.075 <0.1 88.1 UD <0.1 88.1 UD
5 5.2 0.075 <0.1 88.1 UD <0.1 88.1 UD
6 6.1 0.1 <0.1 46.7 5.4 <0.1 46.7 28.2
6 6.2 0.1 <0.1 46.7 0.8 <0.1 46.7 61.6
6a§ 6.3 0.15 NA 49.4 29.8 <0.1 49.4 39.2
6a§ 6.4 0.15 <0.1 49.4 5.3 <0.1 49.4 21.6
7 7.1 0.3 <0.1 23.3 UD <0.1 23.3 67
8 8.1 1.5 <0.1 94.5 98.4 4.26 94.5 97.9
9 9.1 0.6 NA 65.9 75.4 NA 65.9 82.9
10 10.1 0.6 NA 68.1 UD NA 68.1 32
11 11.1 1 NA 86.4 86.5 NA 86.4 54.4
12 12.1 1 <0.1 25.2 8.8 0.41 25.2 17.8
12 12.2 1 <0.1 25.2 UD 0.3 25.2 64.2
12 12.3 1 <0.1 25.2 UD <0.1 25.2 UD
13 13.1 1 1.81 69.4 17.2 4.67 69.4 30.2
UD: both JAK2V617F and Jak2WT clones were undetectable.
NA: not available. Mice died before harvest and bone marrow was harvested for PCR.
Before: before transplantation into NOD/SCID mice; after: 6-week after transplantation in the recipient mouse BM.
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s* Cell dose of CD34+ cells.
† Engraftment was defined by the human CD45+ mouse CD45.1− cells.
‡ Quantification based on real-time quantitative PCR.
§ The same patient #6 with two venesection collections.
eceived comparable number of cells from 5/13 PV patients. The
esults suggested that PB CD34+ cells from PV exhibited engraft-
ent superiority when compared with those from SP. Microarray
tudy comparing BM CD34+ cells from PV patients and healthy
onors demonstrated differential expression of more than 100
enes [20]. It remains to be defined if the differential gene expres-
ion may account for the engraftment capability of PB CD34+ cells
rom PV patients.
Secondly, we demonstrated that the engraftment capability of
V CD34+ cells was unrelated to changes in JAK2V617F clones. In
act, a diminution of the JAK2V617F clone upon engraftment of PV
SC in NOD/SCID mice have also been reported recently [13,14].
ntriguingly, the reduction in JAK2V617F clones was only consis-
ently seen in uninjected but not the injected BM, which might be
xplainedbydefectivehomingof the JAK2V617Fclones to the recip-
entBM.Overall, the results suggested that the JAK2V617Fmutation
as not conferred a proliferative advantage to HSC in NOD/SCID
ouse model.
Thirdly, in contrast toPV, the JAK2V617Fclones inPMFwerepre-
erved in the engrafting cells. Similar results have been reported
ecently, supporting the proposition that PMF contained more
AK2V617F HSC than PV [14]. In addition, we observed a sig-
ificant reduction in JAK2V617F clones when BM cells from ET
atients engrafted in NOD/SCID. In these experiments, BM MNC
rom all patients were similarly transplanted in comparable num-
ers. Therefore, thepreservationor loss of JAK2V617F clones in PMFPlease cite this article in press as: Fung T-K, et al. Differential NOD/SCID
clones from patients with myeloproliferative neoplasms. Leuk Res (2010),
nd ET/PV might reflect a disparate role and/or cytokine depen-
ence of the JAK2V617F clones in PMF versus PV/ET.
Our findings of an engraftment superiority of PB CD34+ cells
n PV and the diminution of JAK2V617F clones upon engraftment
uggested that a pre-JAK2V617Fmutation eventmight be of patho-genetic significance. They also corroborated with the observations
of JAK2V617F-negative clonal hematopoiesis [21–23] and leukemic
transformation in JAK2V617F-positive PV [16,17]. Whether the
JAK2V617F-negative NOD/SCID repopulating cells were of clonal
origin would have to be carefully evaluated. Recent studies have
reported that specific TET2 (ten-eleven translocation2) [24] and
ASXL1 (additional sex comb-like 1) [25] mutations, karyotypic
aberration [26] or specific haplotype [27,28]may also play a patho-
genetic role in PV. These issues should be vigorously investigated.
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